Related Experiment Video

Updated: Dec 26, 2025

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

984

Haprolid Inhibits Tumor Growth of Hepatocellular Carcinoma through Rb/E2F and Akt/mTOR Inhibition

Jun Xing1,2, Vikas Bhuria1, Khac Cuong Bui1

  • 1Department of Internal Medicine I, Medical University Hospital, Eberhard Karls Universität Tübingen, 72076 Tubingen, Germany.

Cancers
|March 12, 2020
PubMed

Insights

Haprolid, a natural compound, effectively inhibits hepatocellular carcinoma (HCC) growth by targeting key molecular pathways. This study highlights its potential as a novel therapeutic agent for advanced HCC.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Hepatocellular carcinoma (HCC) poses a significant global health challenge with limited effective treatments.
  • There is a critical need for innovative therapies to manage advanced HCC.
  • Haprolid, a novel natural compound from myxobacteria, exhibits potent cytotoxic effects against tumor cells, including HCC.

Purpose of the Study:

  • To evaluate the antitumor efficacy of haprolid in HCC.
  • To elucidate the molecular mechanisms underlying haprolid's action in HCC.

Main Methods:

  • In vitro studies used human HCC cell lines (Huh-7, Hep3B, HepG2) to assess cytotoxicity, migration, invasion, apoptosis, and cell-cycle distribution.
  • In vivo efficacy was tested using HCC xenografts in nude mice.
  • Molecular mechanisms were investigated by examining the Rb/E2F and Akt/mTOR pathways using immunoblotting and immunohistochemistry.

Main Results:

  • Haprolid significantly inhibited HCC cell proliferation, migration, and invasion in vitro, suppressing epithelial-mesenchymal transition (EMT).
  • It induced G1/S cell-cycle arrest and apoptosis, downregulating key cell cycle proteins (cyclin A, cyclin B, CDK2) and upregulating inhibitors (p21, p27).
  • Tumor growth was significantly inhibited in vivo, linked to the dual downregulation of Rb/E2F and Akt/mTOR pathways.

Conclusions:

  • Haprolid demonstrates potent antitumor activity against HCC by simultaneously inhibiting the Rb/E2F and Akt/mTOR signaling pathways.
  • These findings suggest haprolid is a promising candidate for palliative therapy in HCC patients.
Abstract

Keywords:
Akt/mTOREMTHCCRb/E2Fapoptosiscell cyclehaprolid

More Related Videos

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.1K
An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

9.3K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K